Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.
Comparing normal and anaemic hands © Shutterstock

Many patients with inflammatory bowel disease, rheumatoid arthritis, and ankylosing spondylitis also develop anaemia, which may impair their ability to exercise and perform normal activities. The cause of this anaemia is complex but is partly attributable to the effects of inflammatory molecules (cytokines) on the bone marrow, which produces new blood cells.

In work recently published in the Journal of Experimental Medicine, a team of researchers from the Kennedy Institute of Rheumatology led by Dr Thibault Griseri, shows that the cytokine interleukin-33 (IL-33) suppresses the production of new red blood cells in an experimental model of inflammatory arthritis and in human cells. This novel effect is caused by a direct effect of IL-33 to inhibit differentiation of red blood cell progenitors into mature cells.

"We are delighted to be able to share our work investigating a new pathway causing anaemia during inflammation. Anaemia is a common problem in patients with inflammatory diseases and we believe this work opens up a new area for development of possible therapies", said James Swann, DPhil student and first author of the paper.

This work identifies a new potential target for treatment of anaemia occurring as a comorbidity in patients with chronic inflammatory diseases.

The study was funded by Versus Arthritis, the Kennedy Trust for Rheumatology Research and the Wellcome Trust, and was a collaboration between the Griseri Lab and the Sansom Group at the Kennedy Institute.

Similar stories

Small mechanical forces in immune cells measured at unprecedented sensitivity

Kennedy Main Research

Oxford researchers have used advanced microscopy techniques to measure previously unseen forces generated by cells during an immune response; a breakthrough for mechanobiology and future advances in health and disease.

NDORMS researchers awarded for Dupuytren research

Awards Hand Kennedy Main

Three NDORMS researchers have received awards from the International Dupuytren Society, a patient organisation that brings together Dupuytren Disease patient societies from across the world.

Hope for rheumatoid arthritis patients who are non-responsive to anti-TNF

Arthritis Kennedy Main

New research published in The Lancet shows that tocilizumab is a more effective treatment than rituximab for rheumatoid arthritis patients with a poor response to anti-tumour necrosis factor (TNF).

A new study maps the expression of innate immune receptors during the course of arthritis

Arthritis Kennedy Main

The research, which was a collaboration with researchers from Oxford University and Queen Mary University of London and published in Journal of Autoimmunity, looked at changes in receptors known as toll-like receptors (TLRs) in arthritis at different stages of disease.

International Women's Day

Department Main

It’s International Women's Day! This year’s theme is #Choosetochallenge. We’re celebrating some of the amazing women at NDORMS, and asking them what changes they’d like to see in medical sciences over the next 100 years.

Patients and carers invited to join new group helping to shape research and treatment of bones, muscles and joints

Main PPI

Oxford’s newest patient partner group, OPEN ARMS launches today to explore the causes, treatment and care for patients with musculoskeletal conditions. Its first three patient partners explain why they are involved and invite other members of the public to join the team.